3 Numbers To Consider Before Buying AstraZeneca plc

Here are three numbers to assess when evaluating AstraZeneca plc (LON: AZN).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

There are always lots of numbers to evaluate when deciding whether or not to buy a particular share.

Today I’m going to look quickly at three numbers that should be considered by anyone thinking about investing in AstraZeneca (LSE: AZN) (NYSE: AZN.US).

Inflation Is Coming

Inflation is out of control, and people are running scared. But right now there’s one thing we believe Investors should avoid doing at all costs… and that’s doing nothing. That’s why we’ve put together a special report that uncovers 3 of our top UK and US share ideas to try and best hedge against inflation… and better still, we’re giving it away completely FREE today!

Click here to claim your copy now!


That’s AstraZeneca’s price-to-earnings (P/E) ratio and it’s well below the FTSE 100 average of around 16.  That difference suggests that either the company’s earnings will be in serious decline for some time (not, perhaps, an uncommon opinion) or else the share price is undervalued. 

Boss Pascal Soriot has made some encouraging changes in his first year at AstraZeneca, such as a major shake-up of its senior management, and a new global strategy that’s clearly focused on R&D.

And there have also been some strategic ‘bolt-on’ acquisitions of companies with candidate products that AstraZeneca can potentially bring to market much faster than it could develop from scratch.

If you believe the company will be able to re-fill its dwindling product pipeline, and that it can develop a range of new treatments that will generate serious revenue, then that P/E of 9 suggests that AstraZeneca might currently be something of a bargain.


That’s AstraZenca’s current percentage yield — around double the FTSE 100 average, and substantially more than you can get from a savings account.

So, even if AstraZeneca’s share price fails to sparkle for some time, a dividend income of 6% on your investment is not to be sniffed at in the meantime.

Of course, the dividend needs to be sustainable. AstraZeneca’s current dividend policy is to maintain or grow the dividend within a limit of two times coverage by core earnings.

Given that it will take some time for new products to come to market, dividend growth may not be realistic for a few years yet. But so long as earnings don’t decline significantly, it should at least be maintainable.


That’s the consensus analyst forecast of the number of US dollars AstraZeneca will be generating in revenue in 2018.  $21bn may well seem a huge amount, but it’s 25% lower than the $28bn of 2012. It’s hardly encouraging to think that the company will be bringing in substantially less money in five years’ time than it did last year.

However, back in March, when it outlined its new strategy to “return to growth” and “achieve scientific leadership“, AstraZeneca said

Based on our focused investment in key growth platforms and our pipeline, we believe we can significantly exceed current market consensus for 2018 revenues of $21.5 billion.

Of course, “significantly exceed” is a somewhat imprecise term, but if that belief is justified, AstraZeneca’s future may be rather brighter than the market thinks, albeit that the light may be at the end of quite a long tunnel.

So there you have them — three numbers which may or may not have some bearing on whether you buy shares in AstraZeneca.

What next?

AstraZeneca is just one of eight dividend-paying blue chips that are firm favourites of investment guru Neil Woodford,  who has a remarkable track record of picking winners.

If you want to know about the other top-quality shares that Woodford currently favours, get your copy of the FREE Motley Fool report, 8 Shares Held By Britain’s Super Investornow!

> Jon does not own any share mentioned in this article.

More on Company Comment

Aerial shot showing an aircraft shadow flying over an idyllic beach
Investing Articles

Rolls-Royce shares are trading for pennies. Should I buy them today?

Just because Rolls-Royce shares cost pennies doesn't make them cheap. Its troubles aren't over yet.

Read more »

Business development to success and FTSE 100 250 350 growth concept.
Investing Articles

8.5% and 9.5% dividend yields! 2 FTSE 100 stocks to buy today

The dividend yields at these brilliant blue-chips sit very close to double digits. I think they could be too good…

Read more »

Investing Articles

Tesco vs Royal Mail: which cheap FTSE 100 share should I buy?

The Tesco and Royal Mail share prices both seem to offer great value at recent levels. So which cheap FTSE…

Read more »

Investing Articles

2 FTSE 100 dividend-paying stocks to buy in an ISA

The deadline for new money going into Stocks and Shares ISAs is just around the corner. Here are two FTSE…

Read more »

Business man on stock market crash financial trade indicator background.
Investing Articles

2 dividend paying banking stocks to combat inflation in 2022

With inflation taking off in the US, the Fed may have to raise rates. Stephen Bhasera believes these banking stocks…

Read more »

Various denominations of notes in a pile
Investing Articles

A high-dividend stock I’d buy now

Why this high-dividend stock is potentially more than just a sleepy cash-cow business and growth looks set to kick in…

Read more »

Investing Articles

2 FTSE 100 dividend stocks I’d aim to never sell

I wouldn't try to hold all my investments forever, but these two FTSE 100 dividend stocks both have many qualities…

Read more »

Scene depicting the City of London, home of the FTSE 100
Investing Articles

With £2,000 to invest, I’d buy these FTSE 100 shares with big dividends

Several FTSE 100 shares pay out big dividends, but I'd start my research with these defensive operators in a growing…

Read more »